An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Science

• Publication date

  2013-05-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/science.1236062PMID 23558169PMCID PMC3985613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disparate Individual Fates Compose Robust CD8+ T Cell Immunity

  2013cited by this paper
• Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

  2012cited by this paper
• Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

  2012cited by this paper
• IDH mutation impairs histone demethylation and results in a block to cell differentiation

  2012cited by this paper
• IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

  2012cited by this paper
• D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.

  2012cited by this paper
• IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

  2011cited by this paper
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

  2011cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Epigenetic choreographers of neurogenesis in the adult mammalian brain

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• Structural studies on human 2-oxoglutarate dependent oxygenases.

  2010cited by this paper
• A feedback loop mediated by degradation of an inhibitor is required to initiate neuronal differentiation.

  2010cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function

  2008cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Genome-wide atlas of gene expression in the adult mouse brain

  2007cited by this paper
• Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

  2002cited by this paper

• Prokaryotic organelle mitochondria drive tumorigenesis: “the original sin”

  2026cites this paper
• Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects

  2026cites this paper
• Metabolic traits of T cells and the implications in autoimmune diseases.

  2026cites this paper
• Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles

  2026cites this paper
• IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis

  2026cites this paper
• Machine Learning-Driven Discovery of Potent IDH1 Mutant Inhibitors from Ultra-Large Ligand Libraries for Targeting Malignant Glioma

  2026cites this paper
• The TET/5hmC Mediated Epigenetic Landscape in Glioma: From Molecular Mechanisms to Therapeutic Targeting and Future Perspectives.

  2026cites this paper
• Epigenetic dysregulation of high-grade gliomas: from heterogeneity to brain network modulation.

  2025cites this paper
• IDH Mutations and Intraoperative 5-ALA Fluorescence in Gliomas: A Systematic Literature Review with Novel Exploratory Hypotheses on the Modulatory Effect of Vorasidenib

  2025cites this paper
• Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth

  2025cites this paper
• The emerging intertwined activities of metabolism and epigenetics unveils culprits and prospects in cancer

  2025cites this paper
• Advances in the management of patients with IDH-mutant glioma

  2025cites this paper
• Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomas

  2025cites this paper
• Metabolism-driven chromatin dynamics: Molecular principles and technological advances.

  2025cites this paper
• Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.

  2025cites this paper
• Targeting PDGFRA-SHP2 Signaling Enhances Radiotherapy in IDH1-Mutant Glioma.

  2025cites this paper
• Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial

  2025cites this paper
• Impairment of Tricarboxylic Acid Cycle (TCA) Cycle in Alzheimer's Disease: Mechanisms, Implications, and Potential Therapies

  2025influential citation
• Metabolic adaptations in cancer progression.

  2025cites this paper
• Synapsin III promotes neuronal-like transdifferentiation of glioblastoma stem cells by disrupting JAG1-Notch1 interaction.

  2025cites this paper
• Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review

  2025cites this paper
• CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia.

  2025cites this paper
• Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.

  2025cites this paper
• Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy

  2025cites this paper
• Metabolic Reprogramming in IDH1/2‑Mutant Gliomas: Redox, Anaplerosis, and Therapeutic Vulnerabilities

  2025cites this paper
• IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity

  2025cites this paper
• Metformin attenuates myocardial ischemia/reperfusion-induced ferroptosis through the upregulation of Nur77-mediated IDH1.

  2025cites this paper
• Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies

  2025cites this paper
• IDH mutant high-grade gliomas

  2025cites this paper
• CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma

  2025influential citation
• Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

  2025cites this paper
• Mechanism analysis and targeted therapy of IDH gene mutation in glioma.

  2025cites this paper
• Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations.

  2025cites this paper
• Autophagy Upregulation in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma Uncovers a Novel Therapeutic Target

  2025cites this paper
• Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice

  2025cites this paper
• Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.

  2025cites this paper
• A patent review of IDH1 inhibitors (2018-present)

  2025cites this paper
• The role of RNA methylation in glioma progression: mechanisms, diagnostic implications, and therapeutic value

  2025cites this paper
• Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors

  2025cites this paper
• A genetically encoded biosensor for point-of-care and live-cell detection of d-2-hydroxyglutarate

  2025cites this paper
• IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming

  2025cites this paper
• Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells

  2025cites this paper
• Molecularly driven therapies in the treatment of primary brain tumors.

  2025cites this paper
• Constructing a novel mitochondrial metabolism-related genes signature to evaluate tumor immune microenvironment and predict survival of colorectal cancer.

  2025cites this paper
• Expanding the landscape of lysine acetylation stoichiometry and clinical impact.

  2025cites this paper
• Scalable co-sequencing of RNA and DNA from individual nuclei

  2025cites this paper
• Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?

  2025cites this paper
• Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism

  2025cites this paper
• Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.

  2024cites this paper
• Olutasidenib for Adults with Relapsed or Refractory Acute Myeloid Leukaemia with Isocitrate Dehydrogenase 1 Mutation

  2024cites this paper
• Improving cancer driver genes identifying based on graph embedding hypergraph and hierarchical synergy dominance model

  2024cites this paper
• GNAO1 overexpression promotes neural differentiation of glioma stem-like cells and reduces tumorigenicity through TRIM21/CREB/HES1 axis

  2024cites this paper
• Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials

  2024cites this paper
• IDH1 R132H and TP53 R248Q Mutations Modulate Glioma Cell Migration and Adhesion on Different ECM Components

  2024cites this paper
• Impact of Sex Hormones on Glioblastoma: Sex-Related Differences and Neuroradiological Insights

  2024cites this paper
• Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System

  2024cites this paper
• Who will benefit from vorasidenib? Review of data from the literature and open questions.

  2024cites this paper
• IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

  2024cites this paper
• Genomic and molecular landscape of gallbladder cancer elucidating pathogenic mechanisms novel therapeutic targets and clinical implications.

  2024cites this paper
• A Review of Advances in Mitochondrial Research in Cancer

  2024cites this paper
• Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs

  2024cites this paper
• Transforming Agents: The Power of Structural Modifications in Glioblastoma Multiforme Therapy.

  2024cites this paper
• Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer.

  2024cites this paper
• Metabolite regulation of epigenetics in cancer.

  2024cites this paper
• Precision Population Cancer Medicine in Brain Tumors: A Potential Roadmap to Improve Outcomes and Strategize the Steps to Bring Interdisciplinary Interventions

  2024cites this paper
• Interplay between epigenetics and metabolism controls cancer stem cell plasticity

  2024cites this paper
• The mitochondrial stress signaling tunes immunity from a view of systemic tumor microenvironment and ecosystem

  2024cites this paper
• Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations

  2024cites this paper
• Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives

  2024cites this paper
• Translational Research Platform for Malignant Central Nervous System Tumors

  2024cites this paper
• TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches.

  2024cites this paper
• The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy

  2024cites this paper
• Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas.

  2024cites this paper
• IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma

  2024cites this paper
• Genomic medicine advances for brain tumors

  2024cites this paper
• IDH inhibition in gliomas: from preclinical models to clinical trials

  2024cites this paper
• Glioma

  2024cites this paper
• CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition.

  2024cites this paper
• State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.

  2024cites this paper
• Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

  2024cites this paper
• Low-Grade Gliomas

  2024cites this paper
• Precision medicine in AML: overcoming resistance

  2024cites this paper
• Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.

  2024cites this paper
• Valproic acid targets IDH1 mutants through alteration of lipid metabolism

  2024cites this paper
• Epigenetic Reprogramming of Autophagy Leads to Uncovering a Novel Therapeutic Target for Mutant IDH1 Astrocytomas

  2024cites this paper
• Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.

  2024cites this paper
• Mitochondria act as a key regulatory factor in cancer progression: current concepts on mutations, mitochondrial dynamics, and therapeutic approach.

  2024cites this paper
• Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

  2024cites this paper
• Whole-tumor histogram analysis of synthetic magnetic resonance imaging predicts isocitrate dehydrogenase mutation status in gliomas

  2024cites this paper
• Metabolic Flexibility: Targeting Mitochondrial Dynamics in Cancer Therapy

  2024cites this paper
• Forward Genetic Screens Identify Mechanisms of Resistance to Small-Molecule Lactate Dehydrogenase Inhibitors.

  2024cites this paper
• Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches

  2024cites this paper
• Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

  2024cites this paper
• The Molecular Landscape of Glioblastoma: Implications for Diagnosis and Therapy

  2024cites this paper
• Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma.

  2024cites this paper
• De novo design of mIDH1 inhibitors by integrating deep learning and molecular modeling

  2024cites this paper
• DSC-MRI derived relative CBV maps synthesized from IVIM-MRI data:Application in glioma IDH mutation status identification

  2023cites this paper
• Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance

  2023influential citation
• Metabolomics and lipidomics strategies in modern drug discovery and development.

  2023cites this paper
• The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

  2023cites this paper